Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 11/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15599223 | 0.80 | SCN9A (0.40) | NOS3NOS1NOS2GAASSTR4 | |
| SCHEMBL17247967 | 0.77 | SSTR4 (0.45) | NOS3NOS1NOS2SSTR4SSTR1 | |
| SCHEMBL29823245 | 0.76 | NOS3 (0.48) | NOS3NOS1NOS2GAASSTR4 | |
| SCHEMBL12093552 | 0.76 | NOS3 (0.48) | NOS3NOS1NOS2GAASSTR4 | |
| SCHEMBL19122393 | 0.73 | SSTR4 (0.40) | NOS3NOS1NOS2SSTR4SSTR1 | |
| SCHEMBL13313012 | 0.73 | PTGS2 (0.53) | NOS3NOS1NOS2SSTR4SSTR1 | |
| SCHEMBL16388761 | 0.72 | NOS3 (0.45) | NOS3NOS1NOS2SSTR4SSTR1 | |
| SCHEMBL11962330 | 0.71 | NOS3 (0.43) | NOS3NOS1NOS2SSTR4CCR1 | |
| SCHEMBL17247993 | 0.71 | SSTR4 (0.43) | NOS3NOS1NOS2SSTR4SSTR1 | |
| SCHEMBL17248014 | 0.69 | NOS3 (0.42) | NOS3NOS1NOS2GAASSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550775-B2 | Substituted triazolopyridines and methods of use thereof | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9493429-B2 | Substituted benzoxazoles and methods of use thereof | GENENTECH, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20160009667-A1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20150322002-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322002-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, SNRPD2, RDX | NOS3 1021/4885NOS1 1122/4885NOS2 1019/4885 |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | P2RX3, P2RX1, P2RX4 | NOS3 920/4885NOS1 1582/4885NOS2 1375/4885 |
| US-20160009667-A1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | CYP4X1, BRIX1, HAX1 | NOS3 2028/4885NOS1 2792/4885NOS2 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.